Dimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal

MT Newswires Live

03/04

Dimerix (ASX:DXB) received an upfront payment of roughly AU$3.2 million from FUSO Pharmaceutical Industries in relation to a license agreement for hypertension and kidney disease drug candidate DMX 200, according to a Tuesday filing with the Australian bourse.

Under the agreement, FUSO has the exclusive rights to commercialize DMX 200 for Focal Segmental Glomerulosclerosis kidney disease in Japan. Dimerix retains all rights to commercialize DMX-200 in all territories other than those covered by FUSO, and two other licensees, namely Advanz Pharma and Taiba, per the filing.

The Australian biopharmaceutical company is entitled to receive further payments once it reaches certain development milestones.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2516136766"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516136766\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2516136766?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-04 11:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516136766","market":"nz","top_or_hot":-1,"title":"Dimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal","media":"MT Newswires Live","content":"<html><body><p> Dimerix (ASX:DXB) received an upfront payment of roughly AU$3.2 million from FUSO Pharmaceutical Industries in relation to a license agreement for hypertension and kidney disease drug candidate DMX 200, according to a Tuesday filing with the Australian bourse.</p><p>Under the agreement, FUSO has the exclusive rights to commercialize DMX 200 for Focal Segmental Glomerulosclerosis kidney disease in Japan. Dimerix retains all rights to commercialize DMX-200 in all territories other than those covered by FUSO, and two other licensees, namely Advanz Pharma and Taiba, per the filing.</p><p>The Australian biopharmaceutical company is entitled to receive further payments once it reaches certain development milestones.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-03-04 11:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Dimerix (ASX:DXB) received an upfront payment of roughly AU$3.2 million from FUSO Pharmaceutical Industries in relation to a license agreement for hypertension and kidney disease drug candidate DMX 200, according to a Tuesday filing with the Australian bourse.</p><p>Under the agreement, FUSO has the exclusive rights to commercialize DMX 200 for Focal Segmental Glomerulosclerosis kidney disease in Japan. Dimerix retains all rights to commercialize DMX-200 in all territories other than those covered by FUSO, and two other licensees, namely Advanz Pharma and Taiba, per the filing.</p><p>The Australian biopharmaceutical company is entitled to receive further payments once it reaches certain development milestones.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2516136766","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516136766","pubTimestamp":1741059169,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dimerix  received an upfront payment of roughly AU$3.2 million from FUSO Pharmaceutical Industries in relation to a license agreement for hypertension and kidney disease drug candidate DMX 200, according to a Tuesday filing with the Australian bourse.Under the agreement, FUSO has the exclusive rights to commercialize DMX 200 for Focal Segmental Glomerulosclerosis kidney disease in Japan. Dimerix retains all rights to commercialize DMX-200 in all territories other than those covered by FUSO, and two other licensees, namely Advanz Pharma and Taiba, per the filing.The Australian biopharmaceutical company is entitled to receive further payments once it reaches certain development milestones.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7508":"医药生物股","XJO.AU":"标普/澳交所 200指数","BK7501":"新冠治疗股","DXB.AU":"DIMERIX LTD","XAO.AU":"标普/澳交所 普通股指数","XKO.AU":"标普/澳交所 300指数","DMX":"DoubleLine Multi-Sector Income ETF"},"translate_title":"Dimerix根据DMX-200许可协议从扶桑制药获得320万澳元预付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXB.AU":0.9,"XKO.AU":0.84,"XAO.AU":0.84,"XJO.AU":0.84,"DMX":1},"content_text":"Dimerix (ASX:DXB) received an upfront payment of roughly AU$3.2 million from FUSO Pharmaceutical Industries in relation to a license agreement for hypertension and kidney disease drug candidate DMX 200, according to a Tuesday filing with the Australian bourse.Under the agreement, FUSO has the exclusive rights to commercialize DMX 200 for Focal Segmental Glomerulosclerosis kidney disease in Japan. Dimerix retains all rights to commercialize DMX-200 in all territories other than those covered by FUSO, and two other licensees, namely Advanz Pharma and Taiba, per the filing.The Australian biopharmaceutical company is entitled to receive further payments once it reaches certain development milestones.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}